These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 38402177

  • 21. Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials.
    Xu B, Kang B, Zhou J.
    Clin Res Cardiol; 2024 Jun; 113(6):910-923. PubMed ID: 38353684
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors.
    Koufakis T, Giannakoulas G, Zebekakis P, Kotsa K.
    Expert Opin Pharmacother; 2022 Feb; 23(3):321-325. PubMed ID: 34761713
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
    Zhou Z, Jardine MJ, Li Q, Neuen BL, Cannon CP, de Zeeuw D, Edwards R, Levin A, Mahaffey KW, Perkovic V, Neal B, Lindley RI, CREDENCE Trial Investigators*.
    Stroke; 2021 May; 52(5):1545-1556. PubMed ID: 33874750
    [Abstract] [Full Text] [Related]

  • 28. Clinical outcomes in heart failure patients with and without atrial fibrillation receiving sodium-glucose cotransporter-2 inhibitor.
    Hu WS, Lin CL.
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):1977-1986. PubMed ID: 36881169
    [Abstract] [Full Text] [Related]

  • 29. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
    Li WJ, Chen XQ, Xu LL, Li YQ, Luo BH.
    Cardiovasc Diabetol; 2020 Aug 26; 19(1):130. PubMed ID: 32847602
    [Abstract] [Full Text] [Related]

  • 30. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
    Jang J, Park S, Kim S, Kim SH, Oh YS, Sa YK, Hwang Y, Jang SW, Ihm SH, Choi Y.
    Eur J Prev Cardiol; 2024 Feb 15; 31(3):320-329. PubMed ID: 37798123
    [Abstract] [Full Text] [Related]

  • 31. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S, Zhou J, Leung KSK, Wai AKC, Jeevaratnam K, King E, Liu T, Wong WT, Chang C, Wong ICK, Cheung BMY, Tse G, Zhang Q.
    Cardiovasc Drugs Ther; 2023 Jun 15; 37(3):561-569. PubMed ID: 35142921
    [Abstract] [Full Text] [Related]

  • 32. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death.
    Claro JC, Candia R, Rada G, Baraona F, Larrondo F, Letelier LM.
    Cochrane Database Syst Rev; 2015 Dec 08; 2015(12):CD008093. PubMed ID: 26646017
    [Abstract] [Full Text] [Related]

  • 33. The Impact of Angiotensin Receptor-Neprilysin Inhibitors on Arrhythmias in Patients with Heart Failure: A Systematic Review and Meta-analysis.
    Mujadzic H, Prousi GS, Napier R, Siddique S, Zaman N.
    J Innov Card Rhythm Manag; 2022 Sep 08; 13(9):5164-5175. PubMed ID: 36196235
    [Abstract] [Full Text] [Related]

  • 34. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
    Zhang N, Wang Y, Tse G, Korantzopoulos P, Letsas KP, Zhang Q, Li G, Lip GYH, Liu T.
    Eur J Prev Cardiol; 2022 Feb 03; 28(17):1961-1973. PubMed ID: 34792124
    [Abstract] [Full Text] [Related]

  • 35. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ.
    Diabetes Metab; 2022 Nov 03; 48(6):101390. PubMed ID: 36170946
    [Abstract] [Full Text] [Related]

  • 36. Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF.
    Pokorney SD, Al-Khatib SM, Sun JL, Schulte P, O'Connor CM, Teerlink JR, Armstrong PW, Ezekowitz JA, Starling RC, Voors AA, Velazquez EJ, Hernandez AF, Mentz RJ.
    Eur J Heart Fail; 2018 Mar 03; 20(3):525-532. PubMed ID: 29266564
    [Abstract] [Full Text] [Related]

  • 37. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, Chu PH.
    Cardiovasc Diabetol; 2020 Nov 06; 19(1):188. PubMed ID: 33158436
    [Abstract] [Full Text] [Related]

  • 38. Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial.
    Eisen A, Ruff CT, Braunwald E, Nordio F, Corbalán R, Dalby A, Dorobantu M, Mercuri M, Lanz H, Rutman H, Wiviott SD, Antman EM, Giugliano RP.
    J Am Heart Assoc; 2016 Jul 08; 5(7):. PubMed ID: 27402235
    [Abstract] [Full Text] [Related]

  • 39. Advanced electrophysiologic mapping systems: an evidence-based analysis.
    Medical Advisory Secretariat.
    Ont Health Technol Assess Ser; 2006 Jul 08; 6(8):1-101. PubMed ID: 23074499
    [Abstract] [Full Text] [Related]

  • 40. Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation.
    Oraii A, Healey JS, Benz AP, Pandey AK, Wong JA, Fonguh S, Wang J, Conen D, Gerstein HC, Connolly SJ, McIntyre WF.
    Can J Cardiol; 2022 Sep 08; 38(9):1434-1441. PubMed ID: 35562018
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.